Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.

Autores de IIS La Fe

• Jaime Sanz Caballer

  Autor

Participantes ajenos a IIS La Fe

• Bazarbachi A
• Schmid C
• Labopin M
• Beelen D
• Wolfgang Blau I
• Potter V
• Niittyvuopio R
• Socié G
• Blaise D
• Ciceri F
• Abou Dalle I
• Spyridonidis A
• Bug G
• Esteve J
• Savani BN
• Nagler A
• Mohty M

Grupos

• Hematología y Hemoterapia

Abstract

Relapsed acute myeloid leukemia (AML) post allogeneic-hematopoietic-cell-transplantation (allo-HCT) has a dismal prognosis.

Keywords

• Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mortality; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous; Young Adult; busulfan; CD135 antigen; cyclophosphamide; granulocyte colony stimulating factor; nucleophosmin; acute graft versus host disease; acute myeloid leukemia; adult; age; aged; allogeneic hematopoietic stem cell transplantation; Article; cancer patient; cancer prognosis; cancer registry; cancer survival; cause of death; chronic graft versus host disease; cohort analysis; controlled study; cytogenetics; cytomegalovirus infection; Europe; female; FLT3 gene; follow up; haploidentical donor; human; human cell; leukemia relapse; leukemia remission; major clinical study; male; multivariate analysis; NPM1 gene; overall survival; retrospective study; sibling